Reata Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RETA Reata Pharmaceuticals Inc
BEST BEST Inc
FUPBY Fuchs Petrolub SE
JACK Jack in the Box Inc
NH NantHealth Inc
PWSC PowerSchool Holdings Inc
AEHL Antelope Enterprise Holdings Ltd
POR Portland General Electric Co
CUBI Customers Bancorp Inc
MITT AG Mortgage Investment Trust Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Price
Delayed
$24.45
Day's Change
-0.08 (-0.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
24.75
Day's Low
23.94
Volume
(Light)

Today's volume of 34,281 shares is on pace to be much lighter than RETA's 10-day average volume of 604,440 shares.

34,281

Display:

Providers:

UpdateCancel
6 providers
September 12, 2022
Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm

EQNX::TICKER_START (NasdaqGM:RETA), EQNX::TICKER_END Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) breached their fiduciary...(Globe Newswire)

September 08, 2022
Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals?

InvestorsObserver issues critical PriceWatch Alerts for NEXI, PIXY, INAB, RLAY, and RETA. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

September 06, 2022
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September...(BusinessWire)

August 09, 2022
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's Ataxia

--FDA Extended PDUFA Date to Provide Time for Full Review of New Submissions --PDUFA Date Extended to February 28, 2023 Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical...(BusinessWire)

August 08, 2022
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

--Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich's Ataxia --Announces Results of New Data and Analyses Submitted to FDA --Conference Call With Management on August 8, 2022, at 8:30 a.m. ET (BusinessWire)

August 01, 2022
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an...(BusinessWire)

July 11, 2022
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.